Pancreatic Cancer Pill Shows Early Promise. Could This Be…

Pancreatic Cancer Pill Shows Early Promise. Could This Be the Next Big Breakthrough? Published: June 2026 | Category: Oncology, Cancer Research, Precision Medicine | TALMedora Editorial Desk Pancreatic cancer remains one of the deadliest cancers in the world. Most patients are diagnosed late, treatment options are limited, and survival rates remain low. Now, researchers have reported encouraging early results from a new experimental pill called daraxonrasib, a targeted therapy designed to attack one of cancer's most notorious genetic drivers: the RAS pathway. The drug is being studied in patients whose cancers carry mutations in genes such as KRAS, NRAS, or HRAS. These mutations help cancer cells grow uncontrollably and are found in many difficult-to-treat cancers, including pancreatic cancer. In an early clinical trial, some patients with advanced pancreatic cancer experienced tumour shrinkage or disease stabilization after taking daraxonrasib. While the st